Table 2 Univariate analysis for IgG4-RD diagnosis
From: IgG4-related disease in patients with idiopathic orbital inflammation
Variables | Biopsy-proven diagnosis | P Value | Odds ratio (95% CI) | P Value | |
|---|---|---|---|---|---|
Non-IgG4-RD (n = 24 patients/30 eyes) | IgG4-RD (n = 21 patients/33 eyes) | ||||
Age (years) | |||||
Mean ± SD | 50.29 ± 17.05 | 55.90 ± 13.36 | 0.230 | ||
Median (min, max) | 49.5 (18, 88) | 57.0 (20, 77) | |||
Age (years) | |||||
< 54 | 13 (54.2) | 7 (33.3) | 0.231 | 1 | |
≥ 54 | 11 (45.8) | 14 (66.7) | 2.36 (0.70, 7.04) | 0.164 | |
Gender | |||||
Male | 5 (20.8) | 11 (52.4) | 0.035 | 1 | |
Female | 19 (79.2) | 10 (47.6) | 0.24 (0.06, 0.88) | 0.032 | |
Laterality | |||||
Unilateral | 18 (75.0) | 9 (42.9) | 0.037 | 1 | |
Bilateral | 6 (25.0) | 12 (57.1) | 4.00 (1.39, 11.53) | 0.010 | |
Duration of symptom presentation (days) | |||||
Mean ± SD | 216.32 ± 253.35 | 579.84 ± 712.05 | 0.031 | ||
Median (min, max) | 120 (3, 1080) | 365 (7, 2555) | |||
Duration of symptom presentation (days) | |||||
< 240 | 14 (63.6) | 6 (31.6) | 0.062 | 1 | |
≥ 240 | 8 (36.4) | 13 (68.4) | 3.79 (1.03, 13.91) | 0.045 | |
Initial VA (logMAR) | |||||
Mean ± SD | 0.39 ± 0.55 | 0.36 ± 0.33 | 0.776 | ||
Median (min, max) | 0.2 (0, 2.3) | 0.3 (0, 1.7) | |||
Initial VA | |||||
Better than 20/50 | 22 (73.3) | 21 (63.6) | 0.208 | 1 | |
20/50 to 20/160 | 5 (16.7) | 11 (33.3) | 1.30 (0.68, 7.76) | 0.178 | |
20/200 or worse | 3 (10.0) | 1 (3.0) | 0.35 (0.03, 3.63) | 0.378 | |
Pain | |||||
No | 19 (79.2) | 16 (76.2) | 1.000 | 1 | |
Yes | 5 (20.8) | 5 (23.8) | 1.19 (0.29, 4.85) | 0.811 | |
Swelling/mass | |||||
No | 7 (29.2) | 2 (9.5) | 0.143 | 1 | |
Yes | 17 (70.8) | 19 (90.5) | 3.91 (0.71, 21.46) | 0.116 | |
Diplopia | |||||
No | 21 (87.5) | 19 (90.5) | 1.000 | 1 | |
Yes | 3 (12.5) | 2 (9.5) | 0.74 (0.11, 4.90) | 0.752 | |
Proptosis | |||||
No | 8 (33.3) | 5 (23.8) | 0.528 | 1 | |
Yes | 16 (66.7) | 15 (76.2) | 1.60 (0.43, 5.96) | 0.484 | |
Red eye/chemosis | |||||
No | 19 (79.2) | 12 (57.1) | 0.196 | 1 | |
Yes | 5 (20.8) | 9 (42.9) | 2.85 (0.77, 10.57) | 0.117 | |
Organ involvement | |||||
Lacrimal gland | 10 (41.7) | 7 (33.3) | 0.073 | 1 | |
Extraocular muscles | 2 (8.3) | 0 (0.0) | 1 (omitted) | – | |
Anterior part | 4 (16.7) | 0 (0.0) | 1 (omitted) | – | |
Apex | 0 (0.0) | 1 (4.8) | 1 (omitted) | – | |
Diffuse pattern | 8 (33.3) | 13 (61.9) | 2.32 (0.63, 8.58) | 0.207 | |
Structural involvement | |||||
Single | 15 (62.5) | 7 (33.3) | 0.075 | 1 | |
Multiple | 9 (37.5) | 14 (66.7) | 3.33 (0.98, 11.37) | 0.055 | |
Enlargement of infraorbital nerve | |||||
No | 15 (83.3) | 6 (31.6) | 0.003 | 1 | |
Yes | 3 (16.7) | 13 (68.4) | 10.83 (2.25, 52.20) | 0.003 | |
Eosinophils (%) | |||||
Mean ± SD | 5.31 ± 5.53 | 9.86 ± 5.54 | 0.009 | ||
Median (min, max) | 2.8 (0.0, 22.0) | 10.1 (1.0, 20.0) | |||
Eosinophils (%) | |||||
≤ 10 | 20 (83.3) | 10 (47.6) | 0.025 | 1 | |
> 10 | 4 (16.7) | 11 (52.4) | 5.50 (1.40, 21.71) | 0.015 | |
Final VA (logMAR) | |||||
Mean ± SD | 0.49 ± 0.75 | 0.25 ± 0.22 | 0.082 | ||
Median (min, max) | 0.15 (0.0, 3.0) | 0.2 (0.0, 0.8) | |||
Final VA | |||||
Better than 20/50 | 20 (66.7) | 25 (75.8) | 0.095 | 1 | |
20/50 to 20/160 | 6 (20.0) | 8 (24.2) | 1.07 (0.32, 3.58) | 0.917 | |
20/200 or worse | 4 (13.3) | 0 (0.0) | 1 (omitted) | – | |
Treatment response | |||||
Complete remission | 10 (41.7) | 5 (23.8) | 0.262 | 1 | |
Partial response | 6 (25.0) | 4 (19.1) | 1.33 (0.25, 7.01) | 0.734 | |
Intermittent episode | 8 (33.3) | 12 (57.1) | 3.00 (0.74, 12.13) | 0.123 | |
Follow-up time (months) | |||||
Mean ± SD | 51.88 ± 39.32 | 58.79 ± 43.20 | 0.577 | ||
Median (min, max) | 44.37 (10.47, 163.40) | 46.20 (7.53, 169.23) | |||